Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum

Rhea-AI Summary

Lexeo Therapeutics (Nasdaq: LXEO) will host a virtual Key Opinion Leader event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Dec 9, 2025 at 3:00 PM ET. The session, titled “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy”, will feature Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford and Director of the Stanford Center for Inherited Cardiovascular Disease, plus an expert clinician scientist who treats patients with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors may register via the company’s News & Events page, and a replay will be archived in Lexeo’s investor section after the event.

News Market Reaction – LXEO

+4.97%

+4.97% Session close to close

In the Dec 4 session, LXEO gained 4.97%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights a virtual Key Opinion Leader session on PKP2-associated arrhythmogenic ...

Analysis

This announcement highlights a virtual Key Opinion Leader session on PKP2-associated arrhythmogenic cardiomyopathy, reinforcing Lexeo’s cardiovascular focus and outreach to clinicians and investors. In recent months, the company reported Q3 2025 results with a net loss of $20.3 million and cash of $122.8 million, completed significant financings, and filed an S-3 resale registration for 1,250,015 warrant shares. Investors may watch future clinical updates and capital markets activity alongside such educational events.

Key Figures

Net loss: $20.3 million Operating expenses: $21.6 million Cash & investments: $122.8 million +5 more

8 metrics

Net loss $20.3 million Q3 2025 net loss (basic and diluted $0.33 per share)

Operating expenses $21.6 million Q3 2025 operating expenses

Cash & investments $122.8 million Cash, cash equivalents and U.S. Treasuries as of Sept 30, 2025

May 2025 proceeds $73.1 million Net proceeds from May 2025 private placement

Oct 2025 financing $143.9 million Estimated net proceeds from October 2025 financings

ATM program size $75.0 million At-the-market program capacity with no sales through Q3 2025

S-8 shares 2,000,000 shares Registered for 2025 Inducement Equity Incentive Plan on Form S-8

S-3 resale shares 1,250,015 shares Shares covered by Form S-3 resale registration for pre-funded warrants

Historical Context

5 past events · Latest: Dec 04 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 04	KOL event announcement	Neutral	+4.6%	Announcement of Dec 9 virtual clinician-focused event at CVCT Forum.
Nov 05	Earnings and pipeline	Positive	-1.8%	Q3 2025 results with FDA feedback, LX2006 data, and financing update.
Oct 20	Offering closing	Negative	-3.8%	Closing of public offering and concurrent private placement raising funds.
Oct 16	Offering pricing	Negative	-0.7%	Pricing of underwritten public offering and concurrent private placement.
Oct 16	Proposed offering	Negative	-0.7%	Announcement of proposed underwritten public offering and private placement.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

LXEO has generally traded lower on financing and offering news, while neutral or operational updates, such as the current KOL event, have coincided with modest positive moves.

Recent Company History

Over the last few months, Lexeo combined capital raising with clinical and corporate progress. October 2025 saw a proposed offering on Oct 16 followed by pricing and closing transactions that raised about $153.8 million. On Nov 5, Q3 2025 results highlighted FDA interactions and interim LX2006 data plus prior $154 million equity financing. The current Dec 9, 2025 virtual KOL event continues the company’s outreach to clinicians and investors, building on prior operational updates.

Key Terms

arrhythmogenic cardiomyopathy, cardiovascular diseases, clinical trialists

3 terms

arrhythmogenic cardiomyopathy medical

"Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22nd"

Arrhythmogenic cardiomyopathy is a heart condition where the muscle tissue of the heart becomes damaged and replaced with scar tissue, which can disrupt the heart's normal rhythm. This can lead to irregular heartbeats and increase the risk of sudden heart failure. For investors, understanding medical conditions like this highlights potential health risks that may impact individuals’ well-being and, indirectly, related industries or markets.

cardiovascular diseases medical

"genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases,"

Cardiovascular diseases are conditions that affect the heart and blood vessels, such as heart attacks, strokes, and chronic circulation problems. They matter to investors because how common these illnesses are, the availability of effective treatments, and regulatory or reimbursement changes directly affect demand for drugs, medical devices, and services—similar to how widespread car issues create steady business for repair shops and parts makers.

clinical trialists medical

"Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum"

Clinical trialists are the researchers, clinicians and scientists who design, run and analyze clinical studies testing new drugs, devices or treatments. They matter to investors because their choices determine how reliably a study is conducted, how quickly results arrive, and how persuasive the data will be to regulators and the market — think of them as the architects and project managers whose work shapes the credibility and timeline of a medical program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced plans to host a virtual event, “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy,” at the 22^nd Global Cardiovascular Clinical Trialists (CVCT) Forum on Tuesday, December 9^th at 3 PM ET.

The session will feature a discussion with Dr. Victoria Parikh, M.D., who is Associate Professor of Cardiovascular Medicine at Stanford University and Director of the Stanford Center for Inherited Cardiovascular Disease, and an expert clinician scientist who cares for people living with PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). Analysts and investors can join the live event by registering on the News & Events page on Lexeo’s website. A replay will be archived on the investor section of Lexeo’s website following the event.

About Lexeo Therapeutics
Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to reshaping heart health by applying pioneering science to fundamentally change how cardiovascular diseases are treated. The Company is advancing a portfolio of therapeutic candidates that take aim at the underlying genetic causes of conditions, including LX2006 in Friedreich ataxia (FA), LX2020 in plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

Media Response:
Media@lexeotx.com

Investor Response:
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

FAQ

When is the Lexeo (LXEO) virtual event at the 22nd CVCT Forum?

The event is scheduled for Tuesday, December 9, 2025 at 3:00 PM ET.

How can investors register for Lexeo's (LXEO) Dec 9, 2025 CVCT virtual session?

Investors can register via Lexeo's News & Events page on the company website.

Who will present for Lexeo (LXEO) at the CVCT Forum on Dec 9, 2025?

The session features Dr. Victoria Parikh, Associate Professor of Cardiovascular Medicine at Stanford, and an expert clinician scientist treating PKP2-ACM.

What is the topic of Lexeo's (LXEO) virtual CVCT presentation?

The presentation is titled “A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy”.

Will Lexeo (LXEO) make a replay of the CVCT session available?

Yes, a replay will be archived in the investor section of Lexeo's website after the event.

Is the Lexeo (LXEO) CVCT session intended for clinicians or investors?

The session is a clinician-focused discussion but analysts and investors are invited to join via registration.